GlobeNewswire Inc.··Telix Pharmaceuticals LimitedTelix's Next-Gen Prostate Cancer Drug Shows Promise With Lower Toxicity Profile
Telix's next-gen prostate cancer therapy shows reduced organ toxicity in Phase 2 trial, expanding into earlier-stage disease applications with expanded clinical potential.
TLXclinical trialprostate cancer